NCT05644067View on ClinicalTrials.gov

Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 25, 2023

Primary Completion Date

April 2, 2024

Study Completion Date

April 2, 2024

Conditions
Malaria
Interventions
BIOLOGICAL

SumayaVac-1(SUM-101)

One immunization every 4 weeks for 3 months (total 3 immunizations)

BIOLOGICAL

Verorab

One immunization every 4 weeks for 3 months (total 3 immunizations)

Trial Locations (1)

74

Ifakara Health Institute, Bagamoyo

All Listed Sponsors
collaborator

Ifakara Health Institute

OTHER

collaborator

Sumaya Biotech GmbH & Co. KG

UNKNOWN

lead

Swiss Tropical & Public Health Institute

OTHER